Pfizer (NYSE:PFE) Trading 1.9% Higher – Time to Buy?

Shares of Pfizer Inc. (NYSE:PFE) traded up 1.9% on Thursday . The company traded as high as $26.95 and last traded at $26.8040. Approximately 34,852,534 shares traded hands during trading, a decline of 18% from the average session volume of 42,401,090 shares. The stock had previously closed at $26.31.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock, adding 38,000 shares. The transaction may signal management’s confidence that the shares are undervalued and supports investor sentiment. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer raised its 2026 revenue outlook to approximately $60.5 billion-$62.5 billion. Stronger performance from recently launched and acquired products, including Seagen and Biohaven assets, is helping offset continued weakness in COVID-related products. Pfizer Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Positive Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s strategy of building growth outside COVID products. Analysts also raised one 2026 EPS estimate to $2.95, close to the $2.98 consensus. Pfizer Chantix Settlement and LITFULO Results
• Neutral Sentiment: Analyst commentary remains focused on whether Pfizer’s launches, acquisitions and pipeline can drive sustained growth from 2029 onward. Broader market caution ahead of inflation data may limit near-term enthusiasm.
• Negative Sentiment: Second-quarter results included a $4.3 billion non-cash intangible-asset impairment and a reported net loss, highlighting portfolio and acquisition-related pressures.
• Negative Sentiment: Commentary warns that part of the 2026 guidance increase relies on products approaching patent expiration, raising concerns about future revenue durability. Pfizer also agreed to a $44 million Chantix settlement, while Arbutus filed patent lawsuits involving Pfizer and BioNTech. Pfizer Guidance and Patent Expiration Risks

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Wolfe Research restated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the stock from $32.00 to $28.00 in a report on Monday, July 6th. CICC Research started coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pfizer in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Stock Up 1.9%

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a fifty day simple moving average of $25.09 and a two-hundred day simple moving average of $26.18. The firm has a market capitalization of $152.77 billion, a PE ratio of 35.27 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the business. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its holdings in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after buying an additional 31,896 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.